

Singapore lays focus on anti-fibrosis therapeutic antibody programme

21 April 2021 | News

GenScript ProBio Enters Collaboration with Singapore's Experimental Drug Development Centre



GenScript Biotech Corporation's biopharmaceutical CDMO segment, GenScript ProBio has announced a collaboration with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, on an anti-fibrosis therapeutic programme to address high unmet medical needs in idiopathic pulmonary fibrosis (IPF).

GenScript ProBio and EDDC are committed to the rapid development of novel antibody therapeutics against IPF. This partnership will leverage synergies in the complementary strengths and capabilities from both drug discovery units using their next-generation technologies to accelerate the development of innovative therapeutics, from target ideation to clinical trials.

EDDC will combine its proprietary High-throughput Antibody Discovery (HiTAD) platform, a high throughput single B-cell cloning and recombinant antibody generation platform that is differentiated from hybridoma technology, and its experience in both *in vitro* and *in vivo* pharmacology; with therapeutic antibody drug discovery capacities from GenScript ProBio, the integrated biologics CDMO segment of GenScript specializing in single B cell, phage display, hybridoma, fully human and bispecific antibody technologies, to facilitate biological drugs from discovery to development and clinical use.

Its differentiated single domain antibody discovery and microfluidic antibody discovery platform from multiple animal species enable the identification of rare and diverse biotherapy candidates that have been difficult to find with previously available technology.